Study finds outcomes of high-risk cancer operations in 80-year-olds worse than reported

December 18, 2007

CHICAGO (December 18, 2007) - New research published in the December issue of The Journal of the American College of Surgeons shows that outcomes of high-risk cancer operations in 80-year-olds are considerably worse than reported in case studies and published survival statistics, which may lead to unrealistic expectations about the safety of these operations in the elderly. With this limited information, elderly patients and their physicians may have difficulty accurately assessing the risks and benefits of major cancer operations.

An increasing number of the very elderly are undergoing major cancer operations as the population ages. Between 1994 and 2003, total surgical discharges after lung, esophageal and pancreatic resection in patients aged 80 years and older increased by 76 percent, and this new number is expected to increase by more than 50 percent by 2020. Current information about outcomes in octogenarians undergoing cancer operations is limited largely to case studies from tertiary care centers, which perform high volumes of these procedures and thus have superior outcomes. For lung, esophageal and pancreatic resection, single-center studies report operative mortality rates between 3 and 4 percent for the very elderly.

"Our study showed that there is a need to improve patient outcomes in the elderly nationwide," said lead investigator of the study Emily Finlayson, MD, MS, assistant professor of surgery, University of Michigan. "Furthermore, it provides a wake up call that the realistic risks and long-term benefits of major cancer operations differ for older patients when compared to their younger counterparts. This difference is essential to consider when surgeons and their older patients are making decisions about whether or not to have this type of surgery, particularly if the patient has other existing medical issues as this further affects the risk-benefit equation."

Researchers conducted a retrospective cohort study of patients undergoing major resections for lung, esophageal and pancreatic cancer using short-term data from the Nationwide Inpatient Sample (NIS) database to assess operative mortality and discharge in octogenarians relative to younger patients (aged 65 to 69 years). Long-term data from the Surveillance and End Results Medicare database was then used to measure late survival in the elderly.

"We believe that our population-based study yields more realistic results because it is representative of patient data from 1,000 hospitals across the country, not just data from the top hospitals," added Dr. Finlayson.

According to the NIS database, between 1994 and 2003 an estimated 200,000 patients aged 65 years and older underwent resection for lung, esophageal or pancreatic cancer. For all three procedures, death during the surgical procedure among octogenarians was substantially higher than that of younger patients for all three cancers (esophagectomy, 19.9 percent versus 8.8 percent, p<0.0001; pancreatectomy, 15.5 percent versus 6.7 percent, p<0.0001; lung resection, 6.9 percent versus 3.7 percent, p<0.0001). Older age was strongly associated with decreased likelihood of being discharged to home after the operation. A large proportion of octogenarians were transferred to extended-care facilities after their operations, ranging from 24 percent after lung resection to 44 percent after esophagectomy. Five-year survival in octogenarians was low for all three cancers: 11 percent after pancreatectomy, 18 percent after esophagectomy and 31 percent after lung-cancer resection. Survival among octogenarians with two or more comorbidities was worse than those with fewer comorbidities.
-end-
About the American College of Surgeons

The American College of Surgeons is a scientific and educational organization of surgeons that was founded in 1913 to raise the standards of surgical practice and to improve the care of the surgical patient. The College is dedicated to the ethical and competent practice of surgery. Its achievements have significantly influenced the course of scientific surgery in America and have established it as an important advocate for all surgical patients. The College has more than 72,000 members and is the largest organization of surgeons in the world. For more information, visit www.facs.org.

Weber Shandwick Worldwide

Related Pancreatic Cancer Articles from Brightsurf:

Precision chemo-immunotherapy for pancreatic cancer?
Pancreatic cancer is highly lethal: according to the National Cancer Institute, only about 10 percent of patients remain alive five years after diagnosis.

Nerves keep pancreatic cancer cells from starving
Pancreatic cancer cells avert starvation by signaling to nerves, which grow into dense tumors and secrete nutrients.

Pancreatic cancer: Subtypes with different aggressiveness discovered
To date, no targeted personalized therapies for pancreatic cancer exist.

Bringing the 'sticky' back to pancreatic cancer
A multidisciplinary team of researchers at Japan's Tohoku University has found that a gene regulator, called BACH1, facilitates the spread of pancreatic cancer to other parts of the body.

Does lung damage speed pancreatic cancer?
High levels of CO2 in the body, due to chronic respiratory disorders, may exacerbate pancreatic cancer, making it more aggressive and resistant to therapy.

Scientists have identified the presence of cancer-suppressing cells in pancreatic cancer
Researchers have identified cells containing a protein called Meflin that has a role in restraining the progression of pancreatic cancer.

Pancreatic cancer discovery reveals how the aggressive cancer fuels its growth
A new discovery about pancreatic cancer sheds light on how the cancer fuels its growth and may help explain how promising cancer drugs work -- and for whom they will fail.

Overcoming resistance in pancreatic cancer
In pancreatic cancer cells' struggle to survive, the cells choose alternative routes when their main pathways are blocked by drugs.

Exposing how pancreatic cancer does its dirty work
Pancreatic cancer is a puzzle -- tumors slough off cells into the bloodstream early in the disease, but the tumors themselves have almost no blood vessels in them.

Targeting cell division in pancreatic cancer
Study provides new evidence of synergistic effects of drugs that inhibit cell division and support for further clinical trials.

Read More: Pancreatic Cancer News and Pancreatic Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.